Achilles Therapeutics plc (ACHL): Price and Financial Metrics
GET POWR RATINGS... FREE!
ACHL Stock Price Chart Interactive Chart >
ACHL Price/Volume Stats
| Current price | $0.91 | 52-week high | $3.45 |
| Prev. close | $0.91 | 52-week low | $0.75 |
| Day low | $0.90 | Volume | 18,611 |
| Day high | $0.92 | Avg. volume | 366,961 |
| 50-day MA | $1.07 | Dividend yield | N/A |
| 200-day MA | $1.91 | Market Cap | 37.15M |
Latest ACHL News From Around the Web
Below are the latest news stories about ACHILLES THERAPEUTICS PLC that investors may wish to consider to help them evaluate ACHL as an investment opportunity.
Is Achilles Therapeutics (ACHL) Outperforming Other Medical Stocks This Year?Here is how Achilles Therapeutics PLC Sponsored ADR (ACHL) and Geron (GERN) have performed compared to their sector so far this year. |
Is Anika Therapeutics (ANIK) Stock Outpacing Its Medical Peers This Year?Here is how Anika Therapeutics (ANIK) and Achilles Therapeutics PLC Sponsored ADR (ACHL) have performed compared to their sector so far this year. |
Achilles Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceLONDON, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that Dr. Iraj Ali, Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Thursday, January 12, 2023, at 8:15 am PST. The event will be held at the Westin St. Francis Hotel in San Francisco, California. A live and archived webcast of the presenta |
Achilles Therapeutics Presents Encouraging Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma at ESMO IO Congress 2022- Early proof-of-concept data support durable clinical benefit including confirmed partial response and stable disease in heavily pre-treated patients with advanced NSCLC - - Safety and tolerability profile potentially expands opportunity to include patients ineligible for high dose lymphodepletion or high dose IL-2 - - Mechanism of action informed by translational science platform’s capability to correlate cNeT with anti-tumor activity - - Additional monotherapy data and initial anti-PD-1 combi |
Achilles Therapeutics to Present Early Proof of Concept of Safety and Clinical Activity of Clonal Neoantigen Reactive T Cells at the ESMO Immuno-Oncology Annual Congress 2022- Durable partial response (PR) and stable disease (SD) achieved in heavily pre-treated non-small cell lung cancer (NSCLC) patients dosed with cNeT monotherapy - - Updated interim Phase I/II results show encouraging safety and tolerability profile with potential for deep and durable responses in NSCLC with cNeT and reduced-dose lymphodepletion and IL-2 - - Company to host a conference call and webcast on December 6, 2022 at 8:00am ET / 1:00pm UK - LONDON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Achill |
ACHL Price Returns
| 1-mo | -17.27% |
| 3-mo | 1.11% |
| 6-mo | -59.73% |
| 1-year | -71.56% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | 1.11% |
| 2022 | -82.04% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...